A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
DRUG: Sugemalimab and Chemotherapy
ORR, Objective response rate, From the initiation of the first dose to 3 years
PFS, Progression-free survival, From the initiation of the first dose to 3 years|OS, Overall survival, From the initiation of the first dose to 3 years|iORR, Objective response rate after induction therapy, From the initiation of the first dose to 3 years|AEs, Adverse events, From the initiation of the first dose to 90 days after the last dose|Measurement of Quality of Life with EORTC QLQ-C30 questionnaire, EORTC QLQ-C30 questionnaire minimum value: not at all (1); maximum: very much (4); higher scores means a worse outcome, From the initiation of the first dose to 3 years|Measurement of Quality of Life with EORTC QLQ-LC13 questionnaire, EORTC QLQ-LC13 questionnaire minimum value: not at all (1); maximum: very much (4); higher scores means a worse outcome, From the initiation of the first dose to 3 years|Measurement of Quality of Life with EORTC EQ-5D-5L VAS questionnaire, The EQ-5D-5L VAS records the respondent's self-rated health on a 10 centimeter (cm) vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being "the worst health you can imagine" and 100 being "the best health you can imagine", From the initiation of the first dose to 3 years
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.